Injectable treatments for hypercholesterolemia
Pro Research Analysisby 
Searched over 200M research papers
Injectable Lipid-Lowering Drugs for Hypercholesterolemia: Key Options
Injectable treatments have become important alternatives for patients with hypercholesterolemia who cannot reach cholesterol goals with oral medications or who are intolerant to statins. Several classes of injectable drugs are now available, each with unique mechanisms and clinical profiles.
PCSK9 Inhibitors: Evolocumab, Alirocumab, Ebronucimab, Recaticimab, and Ongaricimab
Monoclonal antibodies targeting PCSK9, such as evolocumab, alirocumab, ebronucimab, recaticimab, and ongericimab, are highly effective in lowering LDL cholesterol. These drugs can reduce LDL-C by 50% or more and are generally well tolerated, with the most common side effect being mild to moderate injection site reactions. They are especially useful for patients at high cardiovascular risk or with inherited forms of hypercholesterolemia who do not respond adequately to statins or other oral therapies. Newer agents like ebronucimab, recaticimab, and ongericimab have shown similar efficacy and safety in recent trials, with dosing intervals ranging from every 2 weeks to every 12 weeks, offering more flexibility for patients 1467+1 MORE.
Inclisiran: Small Interfering RNA Therapy
Inclisiran is a small interfering RNA (siRNA) that reduces PCSK9 production in the liver. It is administered as a subcutaneous injection initially, then at 3 months, and every 6 months thereafter. Clinical studies have shown that inclisiran can lower LDL-C by about 40–50% in patients with familial hypercholesterolemia and those at risk for atherosclerotic cardiovascular disease. Its safety profile is favorable, with injection site reactions being the most common side effect, and its infrequent dosing schedule is a significant advantage for long-term management 1236.
Evinacumab: ANGPTL3 Inhibitor
Evinacumab is a monoclonal antibody that targets angiopoietin-like protein 3 (ANGPTL3). It is used for patients with refractory hypercholesterolemia who have not achieved LDL-C targets despite maximum tolerated therapy. Evinacumab can reduce LDL-C by more than 50% at the highest doses, and both subcutaneous and intravenous forms are available. The safety profile is acceptable, with serious adverse events being relatively uncommon 15.
Mipomersen: Antisense Oligonucleotide
Mipomersen is an antisense oligonucleotide that inhibits the production of apolipoprotein B-100, a key component of LDL. It is used mainly in familial hypercholesterolemia. Mipomersen can lower LDL-C, but its use is limited by frequent injection site reactions and potential liver enzyme elevations. The overall benefit for patient-important outcomes remains uncertain, and safety concerns have limited its widespread adoption 110.
Safety and Tolerability of Injectable Therapies
Across all injectable lipid-lowering drugs, injection site reactions are the most common side effect, but these are usually mild. Serious adverse events are rare, and these drugs do not increase the risk of muscle symptoms or diabetes, which are concerns with some oral therapies. The choice among these agents often depends on the degree of LDL-C lowering needed, patient preference for dosing frequency, and cost or availability 1234+5 MORE.
Conclusion
Injectable treatments for hypercholesterolemia, including PCSK9 inhibitors, inclisiran, evinacumab, and mipomersen, offer effective options for patients who cannot achieve cholesterol goals with oral medications. These drugs provide significant LDL-C reductions, have favorable safety profiles, and offer flexible dosing schedules, making them valuable tools in the management of high-risk patients.
Sources and full results
Most relevant research papers on this topic